

DR Treatment Coverage

Chabba N, Silwal P, Bascaran C, et al.

Appendix 1: Search StrategyMEDLINE

1. Diabetic Retinopathy/
2. ((diabet\$ or proliferative or non-proliferative) adj4 retinopath\$).tw.
3. diabetic retinopathy.kw.
4. (diabet\$ adj3 (eye\$ or vision or visual\$ or sight\$)).tw.
5. (retinopath\$ adj3 (eye\$ or vision or visual\$ or sight\$)).tw.
6. (DR adj3 (eye\$ or vision or visual\$ or sight\$)).tw.
7. (diabet\$ adj3 macula\$ adj3 oedema).tw.
8. (diabet\$ adj3 macula\$ adj3 edema).tw.
9. (DMO or DME).tw.
10. or/1-9
11. exp light coagulation/
12. photocoagulat\$.tw.
13. (photo adj1 coagulat\$).tw.
14. ((focal or grid) adj3 laser\$).tw.
15. (coagulat\$ or argon or krypton or YAG or diode or micropulse or panretinal).tw.
16. or/11-15
17. Vascular Endothelial Growth Factor A/
18. Endothelial Growth Factors/
19. exp Angiogenesis Inhibitors/
20. (ranibizumab\$ or bevacizumab\$ or avastin\$ or aflibercept\$ or conbercept\$ or OPT 302 or Opthea\$ or RTH258 or faricimab or brolucizumab or leizumabor or abicipar pegol).tw.
21. (anti adj2 VEGF\$).tw.
22. (anti adj1 angiogen\$).tw.
23. (endothelial adj2 growth adj2 factor\$).tw.
24. or/17-23
25. Dexamethasone/
26. Fluocinolone Acetonide/
27. Triamcinolone Acetonide/
28. (dexamethasone or fluocinolone or triamcinolone).tw.
29. or/25-28
30. Vitrectomy/
31. vitrectom\$.tw.
32. PPV\$.tw.
33. or/30-32
34. 16 or 24 or 29 or 33
35. 10 and 34
36. cohort studies/
37. cross-sectional studies/
38. prospective studies/ or retrospective studies/
39. (prospective\$ or retrospective\$ or cohort or crossectional).tw.
40. (cross adj1 section\$).tw.
41. or/36-40

DR Treatment Coverage

Chabba N, Silwal P, Bascaran C, et al.

42. 35 and 41
43. limit 42 to yr="2015 -Current"
44. limit 43 to (comment or editorial or letter or personal narrative)
45. 43 not 44

Embase

1. diabetic retinopathy/
2. ((diabet\$ or proliferative or non-proliferative) adj4 retinopath\$).tw.
3. diabetic retinopathy.kw.
4. (diabet\$ adj3 (eye\$ or vision or visual\$ or sight\$)).tw.
5. (retinopath\$ adj3 (eye\$ or vision or visual\$ or sight\$)).tw.
6. (DR adj3 (eye\$ or vision or visual\$ or sight\$)).tw.
7. diabetic macular edema/
8. (diabet\$ adj3 macula\$ adj3 oedema).tw.
9. (diabet\$ adj3 macula\$ adj3 edema).tw.
10. (DMO or DME).tw.
11. or/1-10
12. laser coagulation/
13. photocoagulat\$.tw.
14. (photo adj1 coagulat\$).tw.
15. ((focal or grid) adj3 laser\$).tw.
16. (coagulat\$ or argon or krypton or YAG or diode or micropulse or panretinal).tw.
17. or/12-16
18. endothelial cell growth factor/
19. angiogenesis inhibitor/
20. (ranibizumab\$ or bevacizumab\$ or avastin\$ or aflibercept\$ or conbercept\$ or OPT 302 or Opthea\$ or RTH258 or faricimab or brolucizumab or leizumabor or abicipar pegol).tw.
21. (anti adj2 VEGF\$).tw.
22. (anti adj1 angiogen\$).tw.
23. (endothelial adj2 growth adj2 factor\$).tw.
24. or/18-23
25. dexamethasone/
26. fluocinolone acetonide/
27. triamcinolone acetonide/
28. (dexamethasone or fluocinolone or triamcinolone).tw.
29. or/25-28
30. exp vitrectomy/
31. vitrectom\$.tw.
32. PPV\$.tw.
33. or/30-32
34. 17 or 24 or 29 or 33
35. 11 and 34
36. cohort analysis/
37. cross-sectional study/
38. prospective study/
39. retrospective study/
40. (prospective\$ or retrospective\$ or cohort or crossectional).tw.

DR Treatment Coverage

Chabba N, Silwal P, Bascaran C, et al.

41. (cross adj1 section\$).tw.
42. or/36-41
43. 35 and 42
44. limit 43 to conference abstract status
45. 43 not 44
46. limit 45 to yr="2015 -Current"
47. limit 46 to (conference paper or "conference review" or editorial or letter or note)
48. 46 not 47